AZN Astrazeneca: on track to deliver ambition of $80B in total revenue in 2030 - Reconfirms total revenue and core EPS guidance(3) for FY 20
AZN Astrazeneca: on track to deliver ambition of $80B in total revenue in 2030 - Reconfirms total revenue and core EPS guidance(3) for FY 2026 - Interim dividend increased 3 cents to $1.06 per share - Disappointed by Cardio-ttransform outcome
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.